Scandinavian ChemoTech: Strong sales in the quarter - Redeye

Redeye provides an update on Scandinavian ChemoTech following the Q2 2024 report. We view the performance from the company to be in line with forecasts, with the deviations partly a result of one-offs. We mostly maintain our estimates and make a miniscule adjustment to our valuation range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1029232/scandinavian-chemotech-highest-quarterly-sales-in-the-companys-history?utm_source=finwire&utm_medium=RSS